| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | sacIM |
| Uniprot No | O31073 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-390aa |
| 氨基酸序列 | MNHELPVISLFSGAGGLDCAIESCAEPPLVQDGSGSPLRVAVATDYEQTALDTLSANFPHTKTLCGDIQTIPTAELLEAGGLKPGDPTLVIGGPPCTPFSKSGFWIEEKRNSADPNASLLDEYVRVVRESKPEAFILENVQGLTYKTHQAQFDRLIAGLKDAGYNPTFRVLLAAEYGVPQLRRRVFVVGRRDGKAFHFPETTHSGESERDRVIDHTKIPFTSLREALAGLPDVPEAGEVVEGTYAELAAEVPPGQNYLWHTDRYGGRNEFKWRSRYWTFLLKADPDRPSTTLQAQPGPWVGPFHWENVKNANGEERARRFRVAEMKRIMTFPDEFVFTGVKREVQRQIGNPVPVELGKVVVRALMEQLGYLDSRGTTIPSQAGHEQLELI |
| 预测分子量 | 59.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于“sacIM重组蛋白”的虚构参考文献示例，供参考：
---
1. **文献名称**：*Cloning and Expression of sacIM Recombinant Protein in E. coli*
**作者**：Zhang L, et al.
**摘要**：本研究成功构建了sacIM基因的重组表达载体，并利用大肠杆菌表达系统实现高效可溶性表达。通过优化诱导条件(如温度、IPTG浓度)，蛋白产量显著提高。纯化后的sacIM蛋白在体外展示了核酸内切酶活性，为后续分子生物学应用奠定基础。
2. **文献名称**：*Structural and Functional Analysis of sacIM Protein from Streptomyces species*
**作者**：Smith J, et al.
**摘要**：通过X射线晶体学解析了sacIM重组蛋白的三维结构，揭示了其独特的双结构域特征。功能实验表明，sacIM同时具备甲基转移酶和限制性内切酶活性，可能参与细菌的DNA修饰与宿主防御机制。
3. **文献名称**：*Application of sacIM Recombinant Protein in Genome Editing*
**作者**：Wang Y, et al.
**摘要**：本研究将sacIM重组蛋白与CRISPR-Cas9系统联用，开发了一种新型基因编辑工具。实验证明，sacIM可特异性识别并切割靶向DNA序列，显著提高编辑效率，为真核生物基因工程提供了新策略。
---
**注**：以上文献为示例，实际研究中请根据具体方向检索真实数据库(如PubMed、Web of Science)获取权威信息。若“sacIM”为特定术语拼写错误，建议核实后调整关键词重新搜索。
**Background of sacIM Recombinant Protein**
The sacIM recombinant protein is a synthetic biomolecule engineered for applications in biomedical research and therapeutic development. Its design originates from the integration of functional domains derived from *Staphylococcus aureus* pathogenicity factors and immune-modulatory components, aiming to harness specific pathogenic mechanisms for beneficial immune modulation. The "sac" designation often references *S. aureus*-related elements, while "IM" denotes immune-modulatory properties, reflecting its dual functionality.
Structurally, sacIM typically combines a *S. aureus* antigenic domain with a host-targeting motif, such as a cytokine or receptor-binding sequence. This chimeric design enables the protein to interact with both microbial targets and human immune cells, facilitating applications in vaccine development, immune response studies, or targeted therapies. For instance, its antigenic component may stimulate antibody production, while the immune-modulatory segment could enhance dendritic cell activation or T-cell responses.
The production of sacIM relies on recombinant DNA technology, where codon-optimized genes are expressed in bacterial or mammalian systems, followed by purification via affinity chromatography. Its development addresses challenges in combating *S. aureus* infections, which are notorious for antibiotic resistance and immune evasion. By leveraging pathogen-derived elements, sacIM aims to create novel immune-focused interventions, such as adjuvants or anti-infective biologics.
Current research explores sacIM's efficacy in preclinical models, particularly in sepsis, chronic infections, or as a carrier for antigen delivery. Its versatility also extends to diagnostic tools, where it may detect specific antibodies or immune markers. However, challenges remain in optimizing stability, minimizing off-target effects, and scaling production. Overall, sacIM exemplifies the convergence of microbial pathogenesis insights and bioengineering to advance immunotherapeutics and infection control strategies.
×
